Literature DB >> 15855645

Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts.

Yoshihiro Mimura1, Hironobu Ihn, Masatoshi Jinnin, Yoshihide Asano, Kenichi Yamane, Kunihiko Tamaki.   

Abstract

The extracellular matrix (ECM) glycoprotein thrombospondin-1 (TSP-1) has been reported to activate the latent complex of transforming growth factor-beta (TGF-beta), the major effects of which in mesenchymal cells is stimulation of the synthesis of ECM. Previous reports suggested the involvement of an autocrine TGF-beta loop in the pathogenesis of scleroderma. In this study, we examined whether TSP-1 plays a role in maintaining the autocrine TGF-beta loop in scleroderma. TSP-1 expression was increased in scleroderma patients compared with in healthy controls in vivo and in vitro. TGF-beta blocking antibody or TGF-beta1 antisense oligonucleotide markedly reduced the up-regulated TSP-1 expression in scleroderma fibroblasts but had little effect on normal fibroblasts. The expression of TSP-1 is up-regulated in scleroderma fibroblasts, possibly at the post-transcriptional level just like in normal fibroblasts stimulated with exogenous TGF-beta1. TSP-1 blocking peptide or antisense oligonucleotide had an inhibitory effect on the up-regulated alpha2I collagen and phosopho-Smad3 levels in scleroderma fibroblasts but had little effects on normal fibroblasts. The transient overexpression of TSP-1 up-regulated alpha2I collagen and phospho-Smad3 levels in normal fibroblasts but had no major effect on scleroderma fibroblasts. Furthermore, these effects of transiently overexpressed TSP-1, which possibly occurred via the activation of latent TGF-beta1, were abolished by the TGF-beta1 antisense oligonucleotide. These results indicate that the constitutive overexpression of TSP-1 may play an important role in autocrine TGF-beta signaling and accumulation of ECM in scleroderma fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855645      PMCID: PMC1606399          DOI: 10.1016/s0002-9440(10)62362-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Differential expression of thrombospondin and cellular fibronectin during remodeling in proliferative glomerulonephritis.

Authors:  J L Barnes; R J Mitchell; J J Kanalas; V L Barnes
Journal:  J Histochem Cytochem       Date:  1999-04       Impact factor: 2.479

2.  The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta.

Authors:  S M Ribeiro; M Poczatek; S Schultz-Cherry; M Villain; J E Murphy-Ullrich
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

3.  Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose.

Authors:  Natalia Yevdokimova; Nadia Abdel Wahab; Roger M Mason
Journal:  J Am Soc Nephrol       Date:  2001-04       Impact factor: 10.121

4.  CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling.

Authors:  A Holmes; D J Abraham; S Sa; X Shiwen; C M Black; A Leask
Journal:  J Biol Chem       Date:  2001-01-04       Impact factor: 5.157

5.  Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat.

Authors:  C Hugo; S J Shankland; R H Pichler; W G Couser; R J Johnson
Journal:  Kidney Int       Date:  1998-02       Impact factor: 10.612

6.  The fibronectin production is increased by thrombospondin via activation of TGF-beta in cultured human mesangial cells.

Authors:  H Tada; S Isogai
Journal:  Nephron       Date:  1998       Impact factor: 2.847

7.  Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors.

Authors:  H Ihn; K Yamane; M Kubo; K Tamaki
Journal:  Arthritis Rheum       Date:  2001-02

8.  Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice.

Authors:  M Streit; P Velasco; L Riccardi; L Spencer; L F Brown; L Janes; B Lange-Asschenfeldt; K Yano; T Hawighorst; L Iruela-Arispe; M Detmar
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

9.  Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36.

Authors:  T Yehualaeshet; R O'Connor; J Green-Johnson; S Mai; R Silverstein; J E Murphy-Ullrich; N Khalil
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

10.  Stimulation of collagen synthesis by the anabolic steroid stanozolol.

Authors:  V Falanga; A S Greenberg; L Zhou; S M Ochoa; A B Roberts; A Falabella; Y Yamaguchi
Journal:  J Invest Dermatol       Date:  1998-12       Impact factor: 8.551

View more
  24 in total

Review 1.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

2.  Initiation of fibrosis in the integrin Αvβ6 knockout mice.

Authors:  Wenjing Wu; Audrey E K Hutcheon; Sriniwas Sriram; Jennifer A Tran; James D Zieske
Journal:  Exp Eye Res       Date:  2018-11-28       Impact factor: 3.467

3.  Impaired expression of thrombospondin-1 in eyes with age related macular degeneration.

Authors:  K Uno; I A Bhutto; D S McLeod; C Merges; G A Lutty
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

Review 4.  Thrombospondin1 in tissue repair and fibrosis: TGF-β-dependent and independent mechanisms.

Authors:  Mariya T Sweetwyne; Joanne E Murphy-Ullrich
Journal:  Matrix Biol       Date:  2012-01-14       Impact factor: 11.583

5.  Decreased astrocytic thrombospondin-1 secretion after chronic ammonia treatment reduces the level of synaptic proteins: in vitro and in vivo studies.

Authors:  Arumugam R Jayakumar; Xiao Y Tong; Kevin M Curtis; Roberto Ruiz-Cordero; Nagarajarao Shamaladevi; Missa Abuzamel; Joshua Johnstone; Gabriel Gaidosh; Kakulavarapu V Rama Rao; Michael D Norenberg
Journal:  J Neurochem       Date:  2014-08-01       Impact factor: 5.372

6.  Transforming growth factor-β in stem cells and tissue homeostasis.

Authors:  Xin Xu; Liwei Zheng; Quan Yuan; Gehua Zhen; Janet L Crane; Xuedong Zhou; Xu Cao
Journal:  Bone Res       Date:  2018-01-31       Impact factor: 13.567

7.  Immunotherapy of systemic sclerosis.

Authors:  Christina G Katsiari; Theodora Simopoulou; Ioannis Alexiou; Lazaros I Sakkas
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

Review 8.  Transforming growth factor β--at the centre of systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

9.  Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1.

Authors:  Lakshmi Venkatraman; Ser-Mien Chia; Balakrishnan Chakrapani Narmada; Jacob K White; Sourav S Bhowmick; C Forbes Dewey; Peter T So; Lisa Tucker-Kellogg; Hanry Yu
Journal:  Biophys J       Date:  2012-09-05       Impact factor: 4.033

Review 10.  Molecular analysis of early host cell infection by Trypanosoma cruzi.

Authors:  Fernando Villalta; M Nia Madison; Yuliya Y Kleshchenko; Pius N Nde; Maria F Lima
Journal:  Front Biosci       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.